

HOME

PHARMA

BIO TECHNOLOGY

MEDICAL TECHNOLOGY

JOBS

FREE SUBSCRIPTION

RSS

NEWS | FEATURES | PEOPLE | EVENTS | R & D | POLICIES | PRODUCTS | TRENDS & ANALYSIS

Wednesday, December 24, 2008

SEARCH

GO!

BIO AUSTRALIA

BIO CHINA

BIO INDIA

BIO INDONESIA

BIO JAPAN

BIO KOREA

BIO MALAYSIA

BIO NEW ZEALAND

BIO PHILIPPINES

BIO SINGAPORE

BIO TAIWAN

BIO THAILAND

Bio Technology >> Events >> Story

US-India BioPharma Summit in June

Bangalore, March 10, 2008: The USA-India Chamber of Commerce (USAIC), a bilateral chamber of commerce aimed at promoting and facilitating trade and investment between the US and India, will organize its annual US-India BioPharma Summit on June 13th, 2008 at Massachusetts.

"Delivering Affordable Innovation through Cross Border Partnerships" is the theme of the summit.

"The US-India BioPharma Summit is part of an ongoing dialogue with all the stakeholders including industry, investors, policy makers and academia," said Karun Rishi, President of the USA-India Chamber of Commerce.

Besides, Kapil Sibal, Minister of Science & Technology, Dr. Surinder Singh, Drug Controller General of India, Dr. M K Bhan, Secretary, Department of Biotechnology, key policy makers from India are likely to attend the summit for which a number of companies from India and the US have already confirmed their participation, a prepared company release said.

Companies like Bristol Myers Squibb, Merck & Co, Eli Lilly, Pfizer, Wyeth, Biogen Idec, Vertex Pharma, Gilead, Jubilant, Advinus, Biocon and Aurigine are likely to participate. Among other are Lehman Brothers, Lazard, TVM Capital, Alexandria Real Estate and a number of investment bankers and venture capitalists.

"We expect a strong participation from emerging companies. This is an ideal platform to understand the trends, policy, forge alliances and business partnerships," Rishi said.

Discussions of the US-India BioPharma Summit 2008 will be centered on a wide range of issues -- Drug Discovery, Research & Development, India's role in Global Bio/Pharma R&D: Transition from "Generics" to "Drug Innovation", In/Out Licensing- New Partnerships and Business Models, Clinical Trials in India: Opportunities and regulatory issues, Neglected Diseases, Innovation & Intellectual Property Protection, Funding Innovation- Opportunities and Challenges, Investment Opportunities, Mergers, Acquisitions and Alliance Dynamics in the Indian Bio-Pharma Industry, Cross border investment trends in the Bio-Pharma industry and Industry-Academic Partnership.

With clinical trial in India generating lot of interest, Karun Rishi said, at the request of the industry a separate discussion session on it has been planned during the summit.

© BioSpectrum Bureau

Advertisement

Get the latest news on
life sciences in your
mail box
Name